Antiphospholipid syndrome secondary prevention

Jump to navigation Jump to search

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome secondary prevention

CDC on Antiphospholipid syndrome secondary prevention

Antiphospholipid syndrome secondary prevention in the news

Blogs on Antiphospholipid syndrome secondary prevention

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Secondary Prevention

Long term anticoagulation

Anticoagulation for venous thrombosis:

Anticoagulation for arterial thrombosis:

For patients having definite diagnosis of antiphospholipid syndrome (APS) and previous history of arterial thrombosis are treated with warfarin and low dose aspirin.

Reduction of reversible risk factors

During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis.

Continuation of anticoagulation:

For patients with APS and a history of an unprovoked thrombotic event, lifelong anticoagulation is recommended.

Patients with definite antiphospholipid syndrome and first venous event* Patients with definite antiphospholipid syndrome and recurrent events despite warfarin with a target intensity of 2·0–3·0 Patients with arterial thrombosis with single positive or low-titre antiphospholipid antibodies Secondary prophylaxis Indefinite anticoagulation to a target INR 2·0–3·0 Indefinite anticoagulation to a target INR 3·0–4·0 or alternative therapies such as extended therapeutic dose low-molecular-weight heparin As per usual recommendations for arterial thrombosis Patients with definite antiphospholipid syndrome and arterial event* Indefinite anticoagulation to a target INR 3·0–4·0 or combined antithrombotic treatment Patients with venous thromboembolism with single positive or low-titre antiphospholipid antibodies As per usual recommendations for deep vein thrombosis treatment INR=international normalised ratio. *Less aggressive or long-lasting antithrombotic treatments might be appropriate in low-risk patients.

References

Template:WH Template:WS